34 results about "Tumor transplantation" patented technology

A 3-methoxy-flavone compound comprises 5,7-dihydroxy-8-(3,3-dimethyl diallyl)-3,3', 4'-trimethoxy flavone and 5, 7-2 dihydroxy-8- (3,3-dimethyl allyl)-3,4'-dimethoxy flavonoe. harmacological test results prove that: the 3-methoxy-flavone compound is an effective fatty acid synthase inhibitor, which shows the broad-spectrum anti-tumor effect in the cytotoxicity tests of various tumor cell lines and has strong tumor growth inhibiting effect on human prostate cancer cell LnCAP, human breast cancer cell ZR-75-1, human lung cancer cell NCI-H23 or human colon cancer cell HCT-116 when applied to human tumor transplant nude mice model tests. In addition, the 3-methoxy-flavone compound reveals no toxicity in mice acute toxicity tests, which then can be used as anti-tumor drug and is a new broad-spectrum anti-tumor drug with great development prospects.

The invention discloses tumor tissue in-vitro preservation liquid and a preparation method thereof. The method comprises the following steps: adding antibiotics into a basic culture medium to obtain a solution A; dissolving taurine into a natural culture medium and adding polyethylene glycol octylphenol ether to obtain a solution B; adding the solution B into the solution A and uniformly mixing to obtain the tumor tissue in-vitro preservation liquid. The in-vitro preservation liquid prepared by the method can be used for keeping the bioactivity of tumor tissues in an in-vitro preservation process, prolonging the in-vitro preservation time of the tumor tissues and improving the success rate of tumor transplantation.

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and / or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and / or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.

The invention discloses a chimeric antigen receptor T lymphocyte and an application thereof to preparation of a product for treating solid tumors. A chimeric antigen receptor in the chimeric antigen receptor T lymphocyte sequentially comprises a human CD8 lead peptide, an anti-Siglec-15 single-chain antibody, a human CD8 hinge transmembrane region, a human 4-1BB intracellular region, a human CD3 zeta intracellular region, a self-cleavage peptide, a CSF2Ra signal peptide, an EGFRt protein, a self-cleavage peptide and a human CD27. Experiments prove that the chimeric antigen receptor T lymphocyte provided by the invention highly expresses IFN gamma and CD107a, has a strong killing function on Siglec-15 positive tumor cells, and has killing efficiency of more than 80% under the condition thatthe effect-target ratio is 1: 1. A tumor transplantation model experiment shows that the chimeric antigen receptor T lymphocyte also has a strong killing function on Siglec-15 positive tumor cells inan animal body.

A method of determining disease diagnosis, progression and response to therapy through the use of xenograft animal models for determining cancer biomarkers is presented. In use, a tumor from a patient is transplanted into an animal model such as a mouse. Expression levels of biomarkers for a disease are assessed in the serum of the animal model. A personalized gene expression profile or biomarker gene signature may be obtained from the expression levels of the biomarkers which can be used to determine disease recurrence, progression and response to therapy.

The invention relates to a drug composition for treating or inhibiting solid tumor, a drug box containing the composition and an anti-solid tumor method. The drug composition includes a graft outsidetumor and an anti-transplantation drug for genetically identical tumor transplantation.

The invention discloses a drug sensitivity analysis method suitable for non-diagnostic and therapeutic purposes of tumor transplantation models, comprising the steps of: selecting a PDX drug sensitivity test response mode; data quality control; and statistically analyzing whether there is a significant tumor volume between each experimental arm difference; compare the tumor volume growth curves between each experimental arm and the blank control group; determine the drug sensitivity level of each experimental mouse, and calculate the drug efficacy evaluation index disease control rate of each experimental arm; calculate each The tumor inhibition rate of the experimental arm; the drug efficacy of different experimental arms was sorted according to the disease control rate and tumor inhibition rate. The method of the invention includes the selection of experimental modes, data quality control, data analysis and result display, and provides a multi-level and complete solution for PDX drug sensitivity analysis.

The invention belongs to the field of bio-pharmaceuticals and particularly relates to expression, purification and self-assembly of TRAIL variant proteins. A recombinant protein is expressed by plasmids comprising the TRAIL fusion proteins in escherichia coli, and the recombinant protein with high activity is produced. The recombinant proteins adopt a centrifugal mode for simple and rapid purification. The purified proteins are self-assembled into particles being 200 nanometers under the physiological conditions. After intravenous injection to a tumor transplantation mouse, the recombinant protein is effectively gathered in the tumor location of the mouse. The recombinant protein is injected into the tumor transplantation mouse in an intraperitoneal injection mode, and tumor growth is effectively suppressed. The recombinant protein subjected to simple process purification is used for oncotherapy.

The invention discloses application of a miR-100 inhibitor in preparation of a medicine for treating a breast cancer. The miR-100 inhibitor is a miR-100 antisense nucleic acid chain, and the sequence is 5'-TTCGGATCTACGGGTT-3'. The miR-100 inhibitor disclosed by the invention can induce apoptosis of tumor cells, growth of tumors in tumor transplanted mice can be effectively induced, the sensitivity of breast cancer cells on chemotherapy medicines is increased, the effect of chemotherapy is improved, and the miR-100 is a latent new target for the medicine for treating the breast cancer, and is a new path for medical therapy.

The invention discloses the use of a compound or a pharmaceutically acceptable salt, ester or solvate thereof in the preparation of a PD-1 / PD-L1 small molecule inhibitor drug. In the present invention, candidate molecules with potential activity in the compound library are screened out through computer simulation, and homogeneous time-resolved fluorescence technology is used to perform high-throughput screening on the binding of candidate molecules to antagonize PD-1 / PD-L1, and select those with better activity. The compound was subjected to a mouse melanoma B16-F10 tumor transplantation experiment, and it was determined that the compound screened by the present invention has anti-tumor activity.

The invention discloses a drug sensitivity reaction analysis method of a patient-derived xenograft. The analysis method comprises the following steps: selecting a PDX (Patient-Derived Xenograft) drugsensitivity testing reaction mode; carrying out data quality control; counting and analyzing whether gross tumor volumes of different experiment arms have remarkable differences or not; comparing whether the experiment arms have differences with gross tumor volume growth curves of blank control groups; determining the drug sensitivity reaction grade of each testing mouse, and calculating the drugeffect evaluation index disease control rate of each experiment arm; calculating the anti-tumor rate of each experiment arm; and according to the disease control rate and the anti-tumor rate, sequencing drug effects of the different experiment arms. The method disclosed by the invention comprises steps of experiment mode selection, data quality control, data analysis and result demonstration, anda multi-layer and complete solving scheme is provided for PDX drug sensitivity analysis.

The invention relates to a special device for tumor transplantation of zebrafish larvae, and a working method of the special device. The special device comprises a box body and a transplantation body,the box body and the transplantation body are each of a rectangular concave body with baffles being arranged around, and the transplantation body and the box body are combined into a whole when the transplantation body is inserted into the box body. Four cuboid vertical columns are arranged at the four corners of the lower bottom face of the transplantation body correspondingly, and a plurality of grooves are formed in the inner bottom face of the transplantation body; and a plurality of drainage holes and a scale are arranged on the inner bottom face of each groove, and a plurality of sets of scale marks are arranged on the left inner side wall and the right inner side wall of each groove. According to the special device, the position of the larvae is fixed during tumor transplantation advantageously, and operation is convenient; and the dosage of transplanted tumor cells can also be quantified accurately. In addition, through the special device, the situation that the larvae are sucked mistakenly in the process of sucking excess liquid before tumor transplantation, and consequently, the larvae are damaged can further be effectively avoided; the transplantation time is saved advantageously, and the situation that the operation time is excessively long, consequently, the larvae die due to water shortage is avoided; and the culture device is ingenious in design concept, convenient to use, obvious in effect and good in effect, experiment accuracy is ensured, and the working efficiency is improved.